Peter Thiel joins board of antibody therapy developer AbCellera

(Reuters) - Billionaire venture capitalist Peter Thiel has joined AbCellera Biologics Inc's board of directors, the Canadian antibody therapy developer said on Thursday.

Thiel, who has backed several startups as they went public, is an existing investor in AbCellera. He joins the startup's board a couple of months after Reuters reported that it had hired investment banks for a U.S. initial public offering, which could come this year.

AbCellera has been working with Eli Lilly and Co (NYSE: LLY) to develop a treatment for the novel coronavirus.

Thiel is known for his early investments in Facebook (NASDAQ: FB) and co-founding electronic payment service provider Paypal Inc (NASDAQ: PYPL). In September, he took data analytics firm Palantir Technologies Inc (NYSE: PLTR) public through a direct-listing.

(Reporting by Tiyashi Datta in Bengaluru; Editing by Amy Caren Daniel)

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• China’s AI leader DeepSeek to file for IPO as soon as this year - report
• Russian strike on Ukraine's Odesa kills three as Moscow, Kyiv battle over Black Sea
• Malaysia says residents at tech commune run by ex-Coinbase exec have valid travel documents